<DOC>
	<DOCNO>NCT00476099</DOCNO>
	<brief_summary>To evaluate 1-year efficacy safety fix combination beclometasone/formoterol pMDI twice daily regimen patient stable severe COPD .</brief_summary>
	<brief_title>Efficacy Safety Study Beclometasone/Formoterol Single Inhaler Patients With COPD</brief_title>
	<detailed_description>The purpose study evaluate long-term efficacy safety fix combination beclometasone/formoterol pMDI twice daily regimen patient stable severe COPD . Patients randomise receive either beclometasone/formoterol budesonide/formoterol DPI formoterol DPI 48 week treatment .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Clinical diagnosis COPD ( accord GOLD guideline ) FEV1 &gt; equal 30 % &lt; 50 % predict normal postbronchodilator ( least 0.7 L absolute value ) COPD symptoms least 2 year At least 1 exacerbation require medical intervention ( oral corticosteroid and/or antibiotic treatment and/or need visit emergency department and/or hospitalization ) within 212 month screen Current previous smoker cumulative exposure smoke 20pack year Current past diagnosis asthma , evidence suggestive asthma Positive FEV1 reversibility test Clinically significant unstable concurrent disease , include clinically significant laboratory abnormality Acute COPD exacerbation lower tract infection and/or treatment oral injectable corticosteroid antibiotic 2 month screen runin Long term oxygen therapy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>